menu
    • menu
    [{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"JPEO-CBRND","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Tecovirimat","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ JPEO-CBRND","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Technologies \/ JPEO-CBRND"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"","graph1":"Immunology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0.40999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"SIGA Technologies \/ BARDA","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Technologies \/ BARDA"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Public Health Agency of Canada","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Public Health Agency of Canada","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Public Health Agency of Canada"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Technologies \/ SIGA Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Oxford University","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Oxford University"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Meridian Medical Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ MERIDIAN MEDICAL TECHNOLOGIES","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ MERIDIAN MEDICAL TECHNOLOGIES"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"SIGA Technologies \/ U.S. Department of Defense","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ U.S. Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Patheon","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SIGA Technologies \/ Patheon Pharmaceuticals Inc.","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Patheon Pharmaceuticals Inc."},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"SIGA Technologies \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"KaliVir Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Tecovirimat","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ KaliVir Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SIGA Technologies \/ KaliVir Immunotherapeutics"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Meridian Medical Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SIGA Technologies \/ SIGA Technologies","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ SIGA Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"ASEAN","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Tecovirimat","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ ASEAN","highestDevelopmentStatusID":"12","companyTruncated":"SIGA Technologies \/ ASEAN"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CLD-400","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"SIGA Technologies \/ SIGA Technologies"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tecovirimat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SIGA Technologies \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"SIGA Technologies \/ Not Applicable"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tecovirimat","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"SIGA Technologies \/ U.S. Department of Defense","highestDevelopmentStatusID":"14","companyTruncated":"SIGA Technologies \/ U.S. Department of Defense"},{"orgOrder":0,"company":"SIGA Technologies","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Monoclonal Antibody-based Therapy","moa":"","graph1":null,"graph2":null,"graph3":"SIGA Technologies","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"SIGA Technologies \/ SIGA Technologies","highestDevelopmentStatusID":null,"companyTruncated":"SIGA Technologies \/ SIGA Technologies"}]

    Find Clinical Drug Pipeline Developments & Deals by SIGA Technologies

    Menu

    SIGA Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Monoclonal Antibody-based Therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Vanderbilt University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            SIGA Enters License with Vanderbilt for Novel Poxvirus Monoclonal Antibodies

                            Details : SIGA gains the exclusive rights for a portfolio of preclinical fully human mAbs which could be used as potential treatments for a broad range of orthopoxviruses, including smallpox and mpox.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 22, 2024

                            Lead Product(s) : Monoclonal Antibody-based Therapy

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Vanderbilt University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : U.S. Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            SIGA Awarded $9M U.S. Defense Contract For TPOXX Procurement

                            Details : The agreement aims for the procurement of Tpoxx (tecovirimat), an antiviral, approved in the US and Canada for the treatment of smallpox and authorized in EU and the UK for smallpox, mpox and cowpox.

                            Brand Name : Tpoxx

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 21, 2024

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : U.S. Department of Defense

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released

                            Details : Tpoxx (tecovirimat) is an oral orthopoxvirus VP37 envelope-wrapping protein inhibitor, Currently, it is being evaluated in the mid-stage clinical trial for the treatment of Monkeypox Virus.

                            Brand Name : Tpoxx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 15, 2024

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : ASEAN

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States

                            Details : The agreement aims to expand access to Tpoxx (tecovirimat), a novel small-molecule drug for the treatment of smallpox, to the member states in the ASEAN.

                            Brand Name : Tpoxx

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 17, 2024

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : ASEAN

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLD-400

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Calidi Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Calidi Collaborates with SIGA to Advance RTNova Virotherapy for Lung Cancer

                            Details : The collaboration aims to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.

                            Brand Name : CLD-400

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 10, 2024

                            Lead Product(s) : CLD-400

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Calidi Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Meridian Medical Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            SIGA Amends International Agreement for Oral TPOXX® Growth

                            Details : SIGA will lead international promotions for oral TPOXX, an FDA-approved drug for smallpox, while maintaining its contractual relationship with Meridian to ensure continuity for key customers.

                            Brand Name : Tpoxx

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Meridian Medical Technologies

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of M...

                            Details : TPOXX (tecovirimat), also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.

                            Brand Name : Tpoxx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2022

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vaccinia-based Cancer Therapy,Tecovirimat

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : KaliVir Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

                            Details : TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors, there is also the potential it could increase immunotherapeutic outcomes.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 15, 2022

                            Lead Product(s) : Vaccinia-based Cancer Therapy,Tecovirimat

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : KaliVir Immunotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Catalent Pharma Solutions

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SIGA Technologies Receives Approval from UK for Tecovirimat

                            Details : TPOXX (tecovirimat, ST-246®), a novel small-molecule drug, is an orthopoxvirus VP37 envelope wrapping protein inhibits the viral maturation of variola virus and other poxviruses by preventing the formation of a secondary viral envelope.

                            Brand Name : Tpoxx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 08, 2022

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Catalent Pharma Solutions

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            SIGA Technologies

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Patheon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

                            Details : TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX und...

                            Brand Name : Tpoxx

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 19, 2022

                            Lead Product(s) : Tecovirimat

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Patheon

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth